For the quarter ending 2026-03-31, VYNE had $604K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-06-30 |
|---|---|---|---|
| Royalty revenues-Royalty | 86 | 570 | - |
| Research and development-Repibresib VYN201 | 150 | 8,487 | - |
| Research and development-Research And Development Of VYN202 | 194 | 7,756 | - |
| Other segment items | 473 | 2,994 | - |
| General and administrative | 3,085 | 11,082 | - |
| Total operating expenses | 3,902 | 30,319 | - |
| Operating loss | -3,816 | -13,011 | - |
| Other income, net | 231 | 629 | - |
| Loss from continuing operations before income taxes | -3,585 | -12,382 | - |
| Income tax expense | 0 | 4 | - |
| Loss from continuing operations | -3,585 | -12,386 | - |
| Income (loss) from discontinued operations, net of income taxes | 0 | 269 | - |
| Net loss | -3,585 | -12,117 | -14,366 |
| Unrealized loss on cash equivalents | - | 0 | 0 |
| Depreciation | 6 | 11 | 12 |
| Stock-based compensation | 474 | 1,016 | 1,292 |
| Amortization of premium or discount on marketable securities | -18 | -240 | -538 |
| Trade receivables, prepaid expenses and other assets and operating lease right-of-use assets | -202 | -3,908 | -306 |
| Trade payables, accrued expenses, employee related obligations and other long-term liabilities | -1,160 | -3,413 | -8,896 |
| Operating lease liabilities | 0 | -25 | -74 |
| Net cash used in operating activities | -4,081 | -10,860 | -22,264 |
| Purchase of property and equipment | - | 0 | - |
| Proceeds from sale and maturity of marketable securities | 4,700 | 20,450 | 47,850 |
| Purchases of marketable securities | 0 | 7,588 | 23,344 |
| Net cash provided by investing activities | 4,700 | 12,862 | 24,506 |
| Withholdings from exercise of options and issuance of shares for stock-based compensation arrangements, net | -15 | -22 | -121 |
| Net cash used in financing activities | -15 | -22 | -121 |
| Increase in cash and cash equivalents | 604 | 1,980 | 2,121 |
| Cash and cash equivalents at beginning of the period | 24,027 | 19,926 | - |
| Cash and cash equivalents at end of the period | 24,631 | 24,027 | - |
VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc. (VYNE)